Published in Leukemia on February 05, 2013
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia (2013) 1.01
Trisomy 21 consistently activates the interferon response. Elife (2016) 0.85
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia (2013) 0.81
Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration. Mol Cell Biol (2014) 0.79
The emerging role of GATA transcription factors in development and disease. Expert Rev Mol Med (2016) 0.79
The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control. Cell Mol Life Sci (2015) 0.78
Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet (2016) 0.77
Myeloid Proliferations Associated with Down Syndrome. J Hematop (2014) 0.75
Intragenic ERG Deletions Do Not Explain the Biology of ERG-Related Acute Lymphoblastic Leukemia. PLoS One (2016) 0.75
Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-positive Prostate Cancer Cells. Mol Cancer Res (2017) 0.75
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature (2010) 3.12
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell (2007) 2.50
ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood (2009) 2.45
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet (2005) 2.44
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2009) 2.42
Cytokine signals modulated via lipid rafts mimic niche signals and induce hibernation in hematopoietic stem cells. EMBO J (2006) 2.18
Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell (2012) 2.15
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood (2009) 1.84
Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood (2009) 1.79
Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood (2005) 1.64
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
ERG is a megakaryocytic oncogene. Cancer Res (2009) 1.57
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood (2008) 1.47
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol (2009) 1.38
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest (2012) 1.29
Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood (2005) 1.23
Promotion and maintenance of leukemia by ERG. Blood (2011) 1.21
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood (2010) 1.03
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood (2011) 1.00
Myeloid leukemia in Down syndrome. Crit Rev Oncog (2011) 0.99
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol (2010) 0.97
Distinct and dynamic requirements for mTOR signaling in hematopoiesis and leukemogenesis. Cell Stem Cell (2012) 0.83
Trisomy 21 tilts the balance. Blood (2008) 0.82
GATA1s goes germline. Nat Genet (2006) 0.81
Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet (2000) 3.50
Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Dev (2000) 2.02
FOG acts as a repressor of red blood cell development in Xenopus. Development (2000) 1.42
MTB, the murine homolog of condensin II subunit CAP-G2, represses transcription and promotes erythroid cell differentiation. Leukemia (2006) 1.28
SC35-mediated reconstitution of splicing in U2AF-depleted nuclear extract. Proc Natl Acad Sci U S A (1997) 1.12
Multiple nuclear factors interact with upstream sequences of differentially regulated beta-conglycinin genes. Plant Mol Biol (1991) 1.08
Erythroid and megakaryocytic transformation. Oncogene (2007) 1.08
Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia (2010) 1.04
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia (2013) 1.01
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J (2011) 0.86
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia. Leukemia (2009) 0.75